The industry’s first ALK degrader starts its first human study.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
It’s less about being fast, more about producing a better product.
The company will try to get the Komzifti QTc prolongation warning removed.
Of 15 treatment-emergent adverse events, only one was deemed related to therapy.
On efficacy, at least, BeOne’s BTK degrader shows an edge.
Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
